European approval covers the treatment of functional mitral regurgitation (FMR). It follows CE mark for degenerative mitral regurgitation (DMR) in April 2025.

Hangzhou, China-based Valgen says the latest authorization positions DragonFly as the first transcatheter mitral valve repair device originating in China to receive European approval for both DMR and FMR indications.